PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE  by Ehlken, B et al.
PSY29
TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN
PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN
AUTOLOGOUS STEM CELLTRANSPLANTATION (ASCT)
RECIPIENTS FROMTHE GERMAN HOSPITALS PERSPECTIVE
Ehlken B1, Berger K1, Leithäuser M2, Koester U3, Schmid C4,
Thalheimer M5, Plesnila-Frank C1, Freund M2, Junghanss C2
1IMS Health, Munich, Germany, 2University Hospital Rostock, Rostock,
Germany, 3Asklepios proresearch, Hamburg, Germany, 4Hospital
Augsburg, Augsburg, Germany, 5University Hospital Heidelberg,
Heidelberg, Germany
OBJECTIVES: To assess treatment patterns, resource consump-
tion, and costs related to febrile neutropenia in patients with
acute leukemia receiving chemotherapy (CT) or in ASCT recipi-
ents. METHODS: A multicentre observational cost study was
conducted in 4 academic hospitals. Interim results are presented
for consecutive adult patients receiving CT or ASCT between
January and November 2006. FN is deﬁned as absolute neutro-
phil count <0.5 ¥ 109/L, fever 38°C and no hint of a non-
infectious fever origin. Resource use was extracted from medical
patient charts. FN related costs for medication, diagnostics,
blood products and re-hospitalization are presented from a hos-
pital provider perspective. Costs for prolonged inpatient stay
due to FN are excluded (under investigation). RESULTS: Of 86
patients, 46 received CT and 40 ASCT. Most common disease
in CT pts was AML (78%) and in ASCT pts multiple myeloma
(50%) and NHL (40%). Mean  SD age was 55  17 yrs (CT)
and 57  11 yrs (ASCT). A total of 96% (CT) and 98%
(ASCT) of cases respectively received neutropenia/infection pro-
phylaxes (G-CSF, GM-CSF, antiinfectives). Mean onset of FN
was 12.2  4.6 and 6.8  2.7 days following start of CT or
ASCT. Mean duration of FN episodes was 5.7  4.8 days (CT)
and 3.7  2.3 days (ASCT); mean treatment duration of FN
was 13.3  8.2 days (CT) and 9.2  3.2 days (ASCT). A total
of 91% (CT) and 95% (ASCT) of patients received antibiotics,
46% (CT) and 28% (ASCT) antifungal agents, and 83% (CT)
and 85% (ASCT) blood products. Mean treatment cost per FN
episode was €4,740  6,914 (Range: 0–32,455) for CT cases
and €1,656  1,225 (range: 0–5,721) for ASCT cases. Main
cost drivers were anti-infective drugs which accounted for 62%
of cost in CT patients, and 43% of cost in ASCT patients.
CONCLUSIONS: FN induces signiﬁcant costs in German hos-
pitals with highest average cost for patients with AL receiving
chemotherapy.
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OBJECTIVES: This study examines factors associated with
health care costs among working age patients with diabetic neu-
ropathic pain (DNP) who are undergoing duloxetine therapy.
METHODS: Using a retrospective cohort design and claims
data, we assessed the predictors of total health care costs over a
one-year follow-up period for patients (18–64 years) with 30+
days of available duloxetine therapy between October 1, 2004
and December 31, 2005. The index date was deﬁned as the ﬁrst
observed pharmacy claim for duloxetine. All individuals selected
had 1+ diabetic neuropathy diagnosis and pain medication dis-
pensed in the 12 months pre-index. Two cohorts of patients were
constructed for individuals with a starting duloxetine dose of 30
(“Dulox30”) and 60 (“Dulox60”) milligrams, respectively. Base-
line demographic and clinical characteristics were assessed for
each cohort, as was prior use of pain medications. Resource
utilization and expenditures were evaluated over 12-months
following index. Multivariate linear regression was performed
to assess whether initial dose of duloxetine was correlated with
health care costs, controlling for demographic and clinical char-
acteristics. RESULTS: We identiﬁed 196 Dulox30 patients and
655 Dulox60 patients. The Dulox30 and Dulox60 groups were
similar by age (55.0 vs 54.2, p = 0.16), and gender (59.2% vs.
58.4% female, p = 0.85). A higher proportion of patients in
Dulox30 group had 4+ diabetes-related complications (26.5% vs
18.4%, p < 0.01) and a Charlson Comorbidity score > 1 (23.0%
vs 17.6%, p = 0.03) relative to those in the Dulox60 group. Prior
use of antidepressants was greater among Dulox60 patients
whereas Dulox30 patients were more likely to receive oxycodone
and hydrocodone (all p < 0.01). After adjusting for patient char-
acteristics, patients in both cohorts had similar total health care
costs (p = 0.95). Factors associated with increased costs included
advancing age, prior pain-related hospitalizations, insulin
therapy, diabetes-related complications, and other chronic
comorbidities. CONCLUSIONS: These ﬁndings indicate that
one-year health care costs were similar for DNP patients receiv-
ing duloxetine therapy, regardless of initial dose.
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OBJECTIVES: Fabry-Anderson disease (a-galactosydase A deﬁ-
ciency) is a rare, x-linked lysosomal storage disorder that can
cause early death from renal, cardiac and cerebrovascular
involvement. The speciﬁc treatment currently available for
Fabry-Anderson disease consists of intravenous enzymatic
replacement therapy (ERT) every 2 weeks of the enzyme
a-galactosidase A. The aim of the study was to evaluate the
economic impact of the Fabry-Anderson Disease treatment.
METHODS: The study was a naturalistic, longitudinal retro-
spective Cost of Treatment study. Patients were enrolled during
the 2001–2004 period and followed until 2007. Direct health
care resources attributable to disease management (drugs, ambu-
latory care, day case treatments, hospitalizations, specialist
visits, diagnostics and laboratory exams) were quantiﬁed using
National Health Service (NHS) tariffs expressed in Euro 2008.
NHS perspective was adopted. Health-related quality of life
information were also collected using SF-36 questionnaire at the
enrolment and after 2 and 5 years of treatment. METHODS: T
RESULTS: We enrolled 15 patients (males 53.3%, mean age of
40.27  14.76 y.o.) from the Nephrology Department of the
University “Federico II” of Naples, with a mean follow-up of
5.53  1.13 years. The average monthly cost of care as
€22,536.46  €2,247.93 per patient, mainly because of treat-
ment products. ERT therapy represented 96.2% of the expenses.
SF-36 results showed a signiﬁcant improvement in all the
domains in particular in the physical domains. CONCLUSIONS:
This is the ﬁrst study evaluating the socio-economic impact of
Fabry-Anderson Disease treatment in Italy. This study showed
that this rare disease requires large amounts of resources for the
management, but it also demonstrated that effective care pro-
vides a satisfactory quality of life. To the best of our knowledge
this seems to be the highest cost of treatment.
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